N-(cyclopropylmethyl)-N-methyl-pyrrolidin-3-amine | 1250494-00-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-(cyclopropylmethyl)-N-methyl-pyrrolidin-3-amine
• 英文别名: N-(cyclopropylmethyl)-N-methylpyrrolidin-3-amine
• CAS: 1250494-00-8
• 化学式: C₉H₁₈N₂
• 分子量: 154.255
• InChiKey: ORAYZRCKIJYCQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1)<br/>[FR] COMPOSÉS AMINOPYRIDINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE PROGÉNITRICE HÉMATOPOÏÉTIQUE 1 (HPK1)
  申请人：ONTARIO INSTITUTE FOR CANCER RES OICR

  公开号：WO2022226667A1

  公开（公告）日：2022-11-03

  The present application relates to substituted heterocyclic compounds of Formula (I) and substituted compound of Formula (II): (I) (II) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting HPK1, such as cancer.

  本申请涉及式(I)的取代杂环化合物和式(II)的取代化合物：(I) (II)或其药学上可接受的盐、溶剂或前药，以及包含这些化合物或其药学上可接受的盐、溶剂或前药的组合物，以及在治疗可通过抑制HPK1治疗的疾病、紊乱或情况中的各种用途，例如癌症。
• SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF
  申请人：Advinus Therapeutics Limited

  公开号：EP2688890B1

  公开（公告）日：2017-08-30
• US9115133B2
  申请人：——

  公开号：US9115133B2

  公开（公告）日：2015-08-25
• [EN] SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF<br/>[FR] COMPOSÉS TRICYCLIQUES SUBSTITUÉS; COMPOSITIONS ET APPLICATIONS MÉDICINALES CORRESPONDANTES
  申请人：ADVINUS THERAPEUTICS LTD

  公开号：WO2012127506A1

  公开（公告）日：2012-09-27

  The present invention relates to substituted fused tricyclic compounds of formula (I) or (Ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by JAK activity. Such conditions include, but not limited to, arthritis, Alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, T-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, T-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or Type I diabetes, complications from diabetes, rheumatoid arthritis, asthma, Crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcerative colitis. The present disclosure also relates to process for the preparation of such compounds, and to pharmaceutical compositions containing them.